Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic.
Newly minted CEO Vas Narasimhan is paying a hefty premium to establish Novartis as a frontrunner in the emerging gene therapy sector.
AMPLEXOR Life Sciences: Helping Life Sciences Firms Optimize Routine Document Production
After a tough few months, sources are telling the Financial Times that Celgene is looking to buy out some biotech names with ties to the company.
The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.
The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need…
Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.
Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.
Six months after getting off its series A, Kymera Therapeutics has nabbed a deal with GlaxoSmithKline, although exact details are under wraps.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
The Terns deal is a poster child of "Lilly China Innovation and Partnerships," a new model in place of Lilly's Shanghai R&D center shuttered…
After selling Kite for $11.9 billion, former executives Arie Belldegrun and David Chang are working on off-the-shelf CAR-T.